A phase I study of cabozantinib (XL184) in patients with renal cell cancer.

ABSTRACT:

Background

Cabozantinib targets tyrosine kinases including the hepatocyte growth factor receptor (MET) and vascular endothelial growth factor (VEGF) receptor 2, which are important drug targets in renal cell carcinoma (RCC).

Patients and methods

This single-arm open-label phase I trial evaluated the safety and tolerability of cabozantinib in heavily pretreated patients with metastatic clear cell RCC.

Results

The study enrolled 25 RCC patients for whom standard therapy had failed. Patients received a median of two prior systemic agents, and most patients had previously received at least one VEGF pathway inhibiting therapy (22 patients [88%]). Common adverse events included fatigue, diarrhea, nausea, proteinuria, appetite decreased, palmar-plantar erythrodysesthesia, an

SUBMITTER: Choueiri TK 

PROVIDER: S-EPMC6279111 | biostudies-literature | 2014 Aug

REPOSITORIES: biostudies-literature